Publications by authors named "Mathiyazhagan Rengasamy"

Article Synopsis
  • Previous research showed that Stempeucel®-1, a type of bone marrow-derived stem cell, effectively treated critical limb ischemia (CLI) in patients with Buerger's disease, and a second generation (Stempeucel®-1A) has been developed to ensure continuity in treatment.
  • *Both versions of Stempeucel® underwent analysis to compare their gene and protein expressions, secreted growth factors, and immunomodulatory activities through various lab tests and an animal model.
  • *Results indicated that both stem cell products had similar angiogenic and immune regulatory properties, and when tested in mice, both versions significantly repaired tissue damage from ischemia, improving function and longevity in the affected limbs.
View Article and Find Full Text PDF

Background: Mesenchymal stromal cells (MSCs) from various tissues have shown moderate therapeutic efficacy in reversing liver fibrosis in preclinical models. Here, we compared the relative therapeutic potential of pooled, adult human bone marrow (BM)- and neonatal Wharton's jelly (WJ)-derived MSCs to treat CCl-induced liver fibrosis in rats.

Methods: Sprague-Dawley rats were injected with CCl for 8 weeks to induce irreversible liver fibrosis.

View Article and Find Full Text PDF

Background & Objectives: Administration of ex vivo-expanded human bone marrow-derived mesenchymal stromal cells (hBMMSC) obtained from single donors has shown therapeutic benefits in both preclinical and clinical studies. In this study, the safety, toxicity and biodistribution profiles of a pooled hBMMSC population, produced from three healthy donors were assessed in rodent and non-rodents.

Methods: The pooled hBMMSC population was characterized by their expression of various cell surface markers, differentiation potential and immunomodulatory activity.

View Article and Find Full Text PDF

Critical limb ischemia (CLI) due to Buerger's disease is a major unmet medical need with a high incidence of morbidity. This phase II, prospective, nonrandomized, open-label, multicentric, dose-ranging study was conducted to assess the efficacy and safety of i.m.

View Article and Find Full Text PDF

Background: Osteoarthritis (OA) is a common and debilitating chronic degenerative disease of the joints. Currently, cell-based therapy is being explored to address the repair of damaged articular cartilage in the knee joint.

Methods: The in vitro differentiation potential of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®) was determined by differentiating the cells toward the chondrogenic lineage and quantifying sulfated glycosaminoglycan (sGAG).

View Article and Find Full Text PDF

Sphingolipids, a family of membrane lipids, are bioactive molecules that participate in diverse functions controlling fundamental cellular processes such as cell division, differentiation, and cell death. Given that most of these cellular processes form the basis for several pathologies, it is not surprising that sphingolipids are key players in several pathological processes. This review discusses the role of the sphingolipid metabolic pathway in diabetes, Alzheimer's disease, and hepatocellular carcinoma, with a special emphasis on the changes in gene expression pattern in these disease conditions.

View Article and Find Full Text PDF